Zkusit zdarma
Prime Medicine, Inc.

Prime Medicine, Inc.

PRME
Cena:
$ 2.97
+0.02 (0.68%)
Valuace
70
Růst
30
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

12:16 07-05-2026

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Conse...

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

8:00 07-05-2026

CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol...

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

8:00 16-04-2026

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechn...

Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units

Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units

20:28 14-04-2026

MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or th...

Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)

Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)

1:10 25-03-2026

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a...

Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey

Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey

2:08 16-03-2026

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep...

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

17:25 06-03-2026

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript...

Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of “Moderate Buy” from Analysts

Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of “Moderate Buy” from Analysts

4:00 06-03-2026

Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been assigned a consensus rating of "Moderat...

182,133 Shares in Prime Medicine, Inc. $PRME Acquired by DNB Asset Management AS

182,133 Shares in Prime Medicine, Inc. $PRME Acquired by DNB Asset Management AS

4:19 04-03-2026

DNB Asset Management AS purchased a new stake in Prime Medicine, Inc. (NYSE: PRME) during the undefi...

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

10:16 03-03-2026

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Conse...

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

8:00 03-03-2026

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, res...

Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of “Moderate Buy” from Brokerages

Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of “Moderate Buy” from Brokerages

4:44 09-02-2026

Shares of Prime Medicine, Inc. (NYSE: PRME - Get Free Report) have been assigned a consensus rating ...

Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day

Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day

7:00 06-02-2026

MONTREAL, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the ...

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

14:16 14-01-2026

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript...

Prime Drink Group Announces First Closing of Private Placement and Grant of Stock Options

Prime Drink Group Announces First Closing of Private Placement and Grant of Stock Options

19:00 31-12-2025

MONTREAL, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the ...

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

13:29 31-12-2025

Prime Medicine is maintained at a "Buy" rating due to advancing in vivo Prime Editing programs for W...

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of “Moderate Buy” by Brokerages

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of “Moderate Buy” by Brokerages

3:24 21-12-2025

Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been given a consensus recommendation of "Mo...

Prime Drink Group Announces Private Placement

Prime Drink Group Announces Private Placement

18:38 17-12-2025

MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the ...

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

8:05 07-12-2025

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechno...

Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)

Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)

2:20 18-11-2025

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report...

close

PRIME DRINK GROUP SECURES EXCLUSIVE NORTH AMERICAN LICENSES FOR BEACH DAY EVERY DAY

06-02-2026
MONTREAL, FEB. 06, 2026 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME MEDICINE TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

07-01-2026
CAMBRIDGE, MASS., JAN. 07, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME DRINK GROUP ANNOUNCES FIRST CLOSING OF PRIVATE PLACEMENT AND GRANT OF STOCK OPTIONS

31-12-2025
MONTREAL, DEC. 31, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME DRINK GROUP ANNOUNCES PRIVATE PLACEMENT

17-12-2025
MONTREAL, DEC. 17, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME MEDICINE ANNOUNCES THE NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION OF PM359 CLINICAL DATA FOR THE TREATMENT OF CHRONIC GRANULOMATOUS DISEASE

07-12-2025
CAMBRIDGE, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME MEDICINE TO PRESENT AT 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

25-11-2025
CAMBRIDGE, MASS., NOV. 25, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME MEDICINE TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

11-11-2025
CAMBRIDGE, MASS., NOV. 11, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

CORRECTION - PRIME MEDICINE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

07-11-2025
-- NEW PRECLINICAL DATA FOR PM577 IN WILSON'S DISEASE (WD) TO BE PRESENTED AT AASLD; ON-TRACK TO FIL...
Více zde

PRIME MEDICINE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

07-11-2025
-- NEW PRECLINICAL DATA FOR PM577 IN WILSON'S DISEASE (WD) TO BE PRESENTED AT AASLD; ON-TRACK TO FIL...
Více zde

PRIME MEDICINE APPOINTS MATTHEW HAWRYLUK, PH.D., M.B.A. AS CHIEF BUSINESS OFFICER

03-11-2025
CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME MEDICINE TO HOST VIRTUAL KOL EVENT TO SHOWCASE WILSON'S DISEASE STRATEGY

30-10-2025
CAMBRIDGE, MASS., OCT. 30, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

07-10-2025
CAMBRIDGE, MASS. , OCT. 07, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHN...
Více zde

PRIME DRINK GROUP PROVIDES BI-WEEKLY MCTO STATUS REPORT

12-09-2025
MONTREAL, SEPT. 12, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE...
Více zde

PRIME DRINK GROUP TERMINATES RIGHTS OFFERING AND ANNOUNCES PRIVATE PLACEMENT

04-09-2025
MONTREAL, SEPT. 04, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE...
Více zde

PRIME DRINK GROUP PROVIDES BI-WEEKLY MCTO STATUS REPORT

29-08-2025
MONTREAL, AUG. 29, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

26-08-2025
CAMBRIDGE, MASS., AUG. 26, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME DRINK GROUP PROVIDES BI-WEEKLY MCTO STATUS REPORT AND ANNOUNCES CLOSING OF PRIVATE PLACEMENT

15-08-2025
MONTREAL, AUG. 15, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME MEDICINE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

07-08-2025
-- ANNOUNCED POSITIVE DATA FROM TWO PATIENTS IN PHASE 1/2 CLINICAL TRIAL IN CHRONIC GRANULOMATOUS DI...
Více zde

PRIME MEDICINE ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

01-08-2025
CAMBRIDGE, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME MEDICINE ANNOUNCES PRICING OF PUBLIC OFFERING

30-07-2025
CAMBRIDGE, MASS., JULY 30, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

PRIME DRINK GROUP EXTENDS EXPIRY DATE OF ITS RIGHTS OFFERING AND ANNOUNCES DELAY IN FILING ANNUAL FINANCIAL STATEMENTS

30-07-2025
MONTREAL, JULY 30, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME MEDICINE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

30-07-2025
CAMBRIDGE, MASS., JULY 30, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNO...
Více zde

CYSTIC FIBROSIS FOUNDATION COMMITS UP TO AN ADDITIONAL $24 MILLION FOR PRIME MEDICINE TO DEVELOP GENE EDITING THERAPY

16-07-2025
BETHESDA, MD.--(BUSINESS WIRE)--TODAY, THE CYSTIC FIBROSIS FOUNDATION ANNOUNCED AN ADDITIONAL INVEST...
Více zde

PRIME MEDICINE ANNOUNCES ADDITIONAL FUNDING OF UP TO $24 MILLION FROM THE CYSTIC FIBROSIS FOUNDATION TO ADVANCE PRIME EDITING TREATMENTS FOR CYSTIC FIBROSIS

16-07-2025
-- EXPANDED FUNDING BUILDS ON THE INITIAL AGREEMENT TO ACCELERATE DEVELOPMENT OF PRIME EDITORS FOR C...
Více zde

PRIME DRINK GROUP ANNOUNCES CHANGE OF AUDITOR

04-07-2025
MONTREAL, JULY 04, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME”) ANNOUN...
Více zde

PRIME DRINK GROUP ANNOUNCES PRIVATE PLACEMENT

02-07-2025
MONTREAL, JULY 02, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME DRINK GROUP ANNOUNCES LAUNCH OF RIGHTS OFFERING

18-06-2025
MONTREAL, JUNE 18, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME DRINK GROUP PROVIDES AN UPDATE ON ITS BOTTLING SUBSIDIARY RECEIVERSHIP

10-06-2025
MONTREAL, JUNE 10, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (“PRIME” OR THE ...
Více zde

PRIME MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

29-05-2025
CAMBRIDGE, MASS., MAY 29, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOL...
Více zde

PRIME MEDICINE ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON OPPORTUNITIES IN LARGE GENETIC LIVER DISEASES, CYSTIC FIBROSIS, AND PARTNERED PROGRAMS ALONGSIDE CEO LEADERSHIP TRANSITION

19-05-2025
-- INITIAL POSITIVE DATA FROM PHASE 1/2 CLINICAL TRIAL OF PM359 IN CGD PROVIDE CLINICAL PROOF-OF-CON...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-12 00:00:008-KStáhnout
2025-11-07 00:00:008-KStáhnout
2025-11-07 00:00:0010-QStáhnout
2025-09-08 01:00:008-KStáhnout
2025-09-08 00:00:008-KStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-08-05 01:00:008-KStáhnout
2025-08-05 00:00:008-KStáhnout
2025-07-31 01:00:008-KStáhnout
2025-07-31 00:00:008-KStáhnout
2025-07-30 01:00:008-KStáhnout
2025-07-30 00:00:008-KStáhnout
2025-07-15 01:00:008-KStáhnout
2025-07-15 00:00:008-KStáhnout
2025-06-05 01:00:008-KStáhnout
2025-06-05 00:00:008-KStáhnout
2025-05-19 01:00:008-KStáhnout
2025-05-19 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-03-18 00:00:008-KStáhnout
2025-03-17 23:00:008-KStáhnout
2025-02-28 00:00:008-KStáhnout
2025-02-28 00:00:0010-KStáhnout
2025-02-27 23:00:008-KStáhnout
2025-02-27 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:008-KStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-10-24 01:00:008-KStáhnout
2024-10-24 00:00:008-KStáhnout
2024-09-30 01:00:008-KStáhnout
2024-09-30 00:00:008-KStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 01:00:0010-QStáhnout
2024-08-08 00:00:008-KStáhnout
2024-08-08 00:00:0010-QStáhnout
2024-06-12 01:00:008-KStáhnout
2024-06-12 00:00:008-KStáhnout
2024-05-21 01:00:008-KStáhnout
2024-05-21 00:00:008-KStáhnout
2024-05-10 01:00:008-KStáhnout
2024-05-10 01:00:0010-QStáhnout
2024-05-10 00:00:008-KStáhnout
2024-05-10 00:00:0010-QStáhnout
2024-03-01 00:00:008-KStáhnout
2024-03-01 00:00:0010-KStáhnout
2024-02-29 23:00:008-KStáhnout
2024-02-29 23:00:0010-KStáhnout
2024-02-16 00:00:008-KStáhnout
2024-02-15 23:00:008-KStáhnout
2024-02-14 00:00:008-KStáhnout
2024-02-13 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2024-01-05 00:00:008-KStáhnout
2024-01-04 23:00:008-KStáhnout
2023-11-03 00:00:008-KStáhnout
2023-11-03 00:00:0010-QStáhnout
2023-11-02 23:00:008-KStáhnout
2023-11-02 23:00:0010-QStáhnout
2023-08-07 01:00:008-KStáhnout
2023-08-07 01:00:0010-QStáhnout
2023-08-07 00:00:008-KStáhnout
2023-08-07 00:00:0010-QStáhnout
2023-06-16 01:00:008-KStáhnout
2023-06-16 00:00:008-KStáhnout
2023-05-17 01:00:008-KStáhnout
2023-05-17 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-03-09 00:00:008-KStáhnout
2023-03-09 00:00:0010-KStáhnout
2023-03-08 23:00:008-KStáhnout
2023-03-08 23:00:0010-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-14 00:00:0010-QStáhnout
2022-11-13 23:00:0010-QStáhnout
2022-10-24 01:00:008-KStáhnout
2022-10-24 00:00:008-KStáhnout
preloader